<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>UTA - methenamine, sodium phosphate, monobasic, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule </strong><br>STEWART-JACKSON PHARMACAL, INC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>UTA CAPSULES</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>UTA CAPSULES for oral administration.<br>Each capsule contains:<br>Methenamine....................................................120 mg<br>Sodium Phosphate Monobasic..........................40.8 mg<br>Phenyl Salicylate................................................36 mg<br>Methylene Blue...................................................10 mg<br>Hyoscyamine Sulfate........................................0.12 mg<br><br>METHENAMINE (hexamethylenetetramine) exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus.  Freely soluble in water, soluble in alcohol and in chloroform.<br><br>SODIUM PHOSPHATE MONOBASIC exists as a white powder.  It is freely soluble in water and practically insoluble in alcohol.<br><br>PHENYL SALICYLATE exists as white crystals with a melting point of 40<span class="Sup">o</span>-43<span class="Sup">o</span>C.  It is very slightly soluble in water and freely soluble in alcohol.<br><br>METHYLENE BLUE (methylthionine chloride) exists as dark green crystals.  It is soluble in water and in chloroform; sparingly soluble in alcohol.<br><br>HYOSCYAMINE SULFATE is an alkaloid of belladonna.  Exists as a white crystalline powder.  Its solutions are alkaline to litmus.  Affected by light.  It is slightly soluble in water; freely soluble in alcohol; sparingly soluble in ether.<br><br>UTA CAPSULES contains inactive ingredients: Dicalcium Phosphate, Gelatin, Microcrystalline Cellulose, Magnesium Stearate, Stearic Acid, Silica, FDC Blue #1 Lake, DC Red #28 Lake and FDC Red #40 Lake.<br><br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action.  It is well absorbed from the gastrointestinal tract. 70%-90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this at pH5, approximately 20% is formaldehyde.  Protein binding - some formaldehyde is bound to substances in the urine and surrounding tissues.  Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.<br><br>SODIUM PHOSPHATE MONOBASIC an acidifier, helps to maintain an acid pH in the urine necessary for the degradation of methenamine.<br><br>PHENYL SALICYLATE releases salicylate, a mild analgesic for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.<br><br>METHYLENE BLUE possesses weak antiseptic properties.  it is well absorbed by the gastrointestinal tract and is srapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine.  75% is excreted unchanged.<br><br>HYOSCYAMINE is a parasympatholytic, which relaxes smooth muscles and thus produces an antispasmodic effect.  It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout body tissues.  Most is excreted in the urine within 12 hours, 13% to 50% being unchanged.  Its biotransformation is hepatic.  Its protein binding is moderate.<br>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>UTA CAPSULES are indicated for the treatment of symptoms of irritative voiding, the relief of local symptoms, such as <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, hypermotility, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, which accompany lower <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, and the relief of urinary tract symptoms caused by diagnostic procedures.<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRADICTIONS:</h1><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the ingredients is possible.  Risk-benefit should be carefully considered when the following medical problems exist: cardiac desease (especially <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span>); gastrointestinal tract obstructive disease; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may be precipitated in <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (such as <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>).<br>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS:</h1>Do not exceed recommended dosage.  If rapid pulse, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> occurs discontinue use immediately.<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS:</h1>
<span class="Bold">Cross sensitivity and/or related problems -</span> patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also.  Delay in gastric emptying could complicate the management of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>.<span class="Bold"><br><br>Pregnancy/Reproduction (FDA Pregnancy category C) -</span>Hyoscyamine and methenamine cross the placenta.  Studies concerning the effect of hyoscyamine and methenamine on pregnancy and reproduction have not been done in animals or humans.  Thus, it is not known whether UTA CAPSULES cause fetal harm when administered to a pregnant woman or affect reproduction capacity.  UTA CAPSULES should be given to a pregnant woman with caution and only if clearly needed.<br><br><span class="Bold">Breast feeding -</span>problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk.  Accordingly UTA CAPSULES should be given to a nursing mother with caution and only if clearly needed.<br><br><span class="Bold">Prolonged use -</span>there have been no studies to establish the safety of prolonged use in humans.  No known long-term animal studies have been performed to evaluate carcinogenic potential.<br><br><span class="Bold">Pediatric -</span>infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.<br><br><span class="Bold">Geriatric -</span>use with caution in elderly patients as thy may respond to usual doses of hyoscyamine with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.<br><br><span class="Bold">Drug Interactions -</span>because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/ antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde).  Doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) inhibitors (concurrent use may intensify antimuscarinic side effects), opioid (narcotic analgesics may result in increased risk of severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>).  Patients should be advised that the urine may become blue to blue-green and the feces may be discolored as a result of the excretion of methylene blue.<br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<span class="Bold">Cardiovascular -</span>rapid pulse, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span><br><br><span class="Bold">Central Nervous system -</span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><br><br><span class="Bold">Respiratory -</span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing<br><br><span class="Bold">Genitourinary -</span>difficult micturition, acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span><br><br><span class="Bold">Gastrointestinal -</span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br><br>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>:</h1>A <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on the use of UTA CAPSUSES has not been reported and due to the nature of its ingredients, abuse of UTA CAPSULES is not expected.<br>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> or gastric lavage.  Slow intravenous administration of physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children) repeated as needed in one to two hours to reverse severe antimuscarinic symptoms.  Administration of small doses of diazepam to control <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  Artificial respiration with oxygen if needed for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.  Adequate hydration.  Symptomatic treatment as necessary.<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<span class="Bold">Adults:</span>one capsule 4 times per day followed by liberal fluid intake.<br><br><span class="Bold">Older children -</span>Dosage must be individualized by physician.  Not recommended for use in children six years of age or younger.<br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>UTA Capsules are blue/blue capsules imprinted "SJ 646" NDC 45985-646-01, bottles of 100 capsules and a unit dose pack of 1 capsule (45985-646-99).<br>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12"></a><p></p>
<h1>STORAGE:</h1>Dispense in a tight, light-resistant container as defined in USP.<br><br>Store at controlled room temperature, 15<span class="Sup">0</span>-30<span class="Sup">0</span>C (59<span class="Sup">0</span>-86<span class="Sup">0</span>F).  Keep container tightly closed.<br><br><span class="Bold">Keep this and all drugs out of the reach of children.<br><br>Manufactured by:<br>Contract Pharmacal Corporation<br>Hauppauge, NY 11788<br><br>Distributed by:<br></span>Stewart-Jackson Pharmacal<br>4200 Northside Parkway NW, Building 12<br>Atlanta, GA 30327<br><br>Rev. 05/09<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>NDC 45985-646-01<br><br>UTA CAPSULE<br><br>Each capsule contains:<br><br>Methenamine....................................................120 mg<br>Sodium Phosphate Monobasic..........................40.8 mg<br>Phenyl Salicylate................................................36 mg<br>Methylene Blue...................................................10 mg<br>Hyoscyamine Sulfate........................................0.12 mg<br><br><br><span class="Bold">Rx ONLY<br>CONTENTS:100 Capsules<br><br>PHARMACIST:</span>Preserve and dispense in tight, light-resistant containers with child-resistant closures.<br><br><span class="Bold">WARNING:</span>Keep this and all drugs out of the reach of children.<br><br>Store at controlled room temperature, 15<span class="Sup">0</span>-30<span class="Sup">0</span>C (59<span class="Sup">0</span>-86<span class="Sup">0</span>F)<br><br><span class="Bold">DOSAGE AND ADMINISTRATION:<br>Adults:</span>One capsule 4 times per day followed by liberal fluid intake. <span class="Bold">Older children-</span>Dosage must be individualized by physician.  Not recommended for use in children six years of age or younger.<br><br><span class="Bold">Manufactured by:<br></span>Contract Pharmacal Corporation<br>Hauppauge, NY 11788<br><br><span class="Bold">Distributed by:<br></span>Stewart-Jackson Pharmacal<br>4200 Northside Parkway NW,<br>Building 12<br>Atlanta, GA 30327<br><br><div class="Figure"><img alt="Description" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=206ac12b-a081-4e37-aa0e-73b8794608d8&amp;name=MM1.jpg"></div>
<br><div class="Figure"><img alt="Ingredients" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=206ac12b-a081-4e37-aa0e-73b8794608d8&amp;name=MM2.jpg"></div>
<br><div class="Figure"><img alt="Dosage and Administration" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=206ac12b-a081-4e37-aa0e-73b8794608d8&amp;name=MM3.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UTA 		
					</strong><br><span class="contentTableReg">methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, hyoscyamine sulfate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:45985-646</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Methenamine</strong> (Methenamine) </td>
<td class="formItem">Methenamine</td>
<td class="formItem">120 mg  in 206.92 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Sodium Phosphate, Monobasic</strong> (PHOSPHORIC ACID) </td>
<td class="formItem">Sodium Phosphate, Monobasic</td>
<td class="formItem">40.8 mg  in 206.92 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Phenyl Salicylate</strong> (Phenyl Salicylate) </td>
<td class="formItem">Phenyl Salicylate</td>
<td class="formItem">36 mg  in 206.92 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Methylene Blue</strong> (Methylene Blue) </td>
<td class="formItem">Methylene Blue</td>
<td class="formItem">10 mg  in 206.92 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Hyoscyamine Sulfate</strong> (Hyoscyamine) </td>
<td class="formItem">Hyoscyamine Sulfate</td>
<td class="formItem">.12 mg  in 206.92 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SJ;646</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:45985-646-01</td>
<td class="formItem">10020692 mg in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:45985-646-99</td>
<td class="formItem">206.92 mg in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">08/01/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STEWART-JACKSON PHARMACAL, INC
							(101802361)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CONTRACT PHARMACAL CORPORATION</td>
<td class="formItem"></td>
<td class="formItem">057795122</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7adea54e-010d-4ad5-a605-c717239b0ada</div>
<div>Set id: 206ac12b-a081-4e37-aa0e-73b8794608d8</div>
<div>Version: 1</div>
<div>Effective Time: 20091116</div>
</div>
</div> <div class="DistributorName">STEWART-JACKSON PHARMACAL, INC</div></p>
</body></html>
